Goldman Sachs Sticks to Novo Nordisk Hold Rating Amid Mixed Analyst Opinions
Goldman Sachs has maintained its Hold rating for Novo Nordisk (0QIU), sticking to this assessment despite recent earnings reports. Analyst James Quigley set a price target of DKK285.00, which is based on the company's quarterly revenue and net profit.
In the second quarter ending June 30, Novo Nordisk reported a revenue of DKK78.49 billion and a net profit of DKK20.99 billion. This marks a slight increase from last year's figures, with the company earning DKK76.86 billion in revenue and DKK26.5 billion in net profit.
It's worth noting that Novo Nordisk has received mixed opinions from analysts. On September 17, UBS's Matthew Weston maintained a Hold rating for the company, while Deutsche Bank issued a Sell rating on September 15. Goldman Sachs' Quigley has an average return of -6.6% and a success rate of 42.44%, according to TipRanks.